TGFB1 and diabetic kidney disease: Li et al. showed that isoliquiritigenin alleviated mesangial ECM deposition by inhibiting the TGF-β1 signaling pathway in rats with diabetic nephropathy-induced by high glucose (Table 1) (Li et al., 2010a).